Meletios A. Dimopoulos, MD
New options for patients with hematologic malignancies stemming from recent FDA approvals are making an impact on treatment strategies recommended in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
The FDA recently approved ibrutinib (Imbruvica) plus rituximab (Rituxan) for the treatment of Waldenström macroglobulinemia (WM), or lymphoplasmacytic lymphoma, a rare form of B-cell lymphoma that is characterized by bone marrow infiltration by lymphoplasmacytic cells.2
The approval expands the label of ibrutinib in WM from its currently approved use as monotherapy to include the first nonchemotherapy combination in this malignancy.
... to read the full story